Status and phase
Conditions
Treatments
About
This is a phase Ⅲ, multicenter, randomized, double-blind, study to evaluate the efficacy and safety of JMT103 in patients with bone metastases from malignant solid tumors. The purpose of this study is to determine if JMT103 is non-inferior to zoledronic acid.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
1,360 participants in 2 patient groups
Loading...
Central trial contact
Zefei Jiang, M.D; Clinical Trials Information Group officer
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal